Professor Tim Maughan
Tim studied medicine at Cambridge and UCH, London and undertook his research training at Cambridge under Prof Norman Bleehen at the MRC Clinical Oncology and Radiotherapeutics Unit.
Thereafter he worked as an NHS consultant Clinical Oncologist in Cardiff, becoming Professor of Cancer Studies in 2007. During that time, he established the first clinical research network, the Wales Cancer Trials Network, and was subsequently involved in the development of the clinical research networks across the UK.
Tim’s research has focused on colorectal cancer: he leads the FOCUS4 trial of molecular selection of treatment with Richard Wilson from Belfast, which is now recruiting patients across the UK. At Paddy’s suggestion he also led the bid for the first MRC stratified medicine consortium in cancer which is jointly led between Oxford and Belfast.
From 2008-10, Professor Maughan was the founding chair of the NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad), which has a broad remit to enhance radiotherapy research in the UK. Professor Maughan was appointed Professor of Clinical Oncology and Deputy Director of the MRC-CRUK Oxford Institute of Radiation Oncology, Department of Oncology at the University of Oxford in 2011.
THE CHALLENGE AND THE PROMISE OF PRECISION MEDICINE IN CANCER
Precision medicine by its very name makes a promise of treatment which is precisely tailored for the individual. This has proved an elusive goal in cancer which by its very nature not only varies from person to person but is also evolving in time and place within the individual.
Targeted therapeutics have delivered a few notable advances, but overall the field has seen short-lived responses and a lack of long term disease control. Major clinical trial programmes have been able to allocate less than 20% of patients to ‘targeted therapies’ on the basis of the patient’s tumour genetics. Our efforts in colorectal cancer reveal a complex co-evolution of the tumour and its micro-environment, with critical cross talk between the malignant epithelium, the stroma and the immune response. We have shown that this interaction appears to determine the response to standard chemoradiation in rectal cancer, through TGF signalling and immune exclusion. The cytokine IL-23 pathway drives poor prognosis in KRAS mutant CRC. Stromal derived Gremlin signalling drives tumourigenesis.
This tumour microenvironment cross talk is not revealed by analysis of genetic sequence but by transcriptional profiles reflecting the altered biological behaviour of stroma, epithelial and immune elements. This insight drives us to focus on detailed analysis of the conversation going on between elements of the tumour microenvironment, how they together behave as a malignant tissue and how that conversation can be manipulated to clinical benefit. This broader paradigm may help in identifying new ways to make progress in challenging malignancies where both targeted therapy and immunotherapy have so far proved unsuccessful.
3D mammosphere culture of breast epithelial cell line MCF10A.
Courtesy of Dr. Emer Bourke, NUI Galway
Phospho-Akt expression and localisation
Mediated by VEGF in A549 lung cancer cells. Visualised by high content image analysis.
Metaphase chromosome spread of Jurkat T-lymphoma cells
Apoptosis assessment of SKMES-1 lung cancer cells
Using a multiparameter apoptosis staining kit, showing cell nuclei (blue), actin (green) and mitochondrial activity (orange).
Mitotic Chronic Myelogenous Leukaemia K562 Cells
Cell to Cell Tweeting
Via nanoparticles (red) in Triple Negative Breast Cancer (TNBC)
Courtesy of Sinéad Lindsay, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD) Ireland.
Confocal Microscopy Analysis
Of phospho-Akt expression in H460 lung cancer cells in response to hypoxia (0.5% O2).
We have a number of membership categories available. Find out which membership suits you.
Due to COVID restrictions we have yet to confirm the dates for 57th Annual Conference.
Please check back here later in 2020 to check for updates.
IACR Public Engagement
Would you like to know more about how we involve patients in research, our fundraising, and lay seminars?
The Irish Association for Cancer Research will support a limited number of Educational Grants that will be made available to postgraduate PhD researchers who have been affected by the Covid-19 pandemic. We acknowledge that many of our members have been significantly impacted by the recent pandemic that may have affected their ability to continue and/or complete research projects.
for Cancer Research
9A Coolkill, Sandyford
Dublin 18, Ireland
+353 (0)295 8859
Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations, Charities Regulator, 3 George's Dock, IFSC, Dublin 1, D01 X5X0, Ireland.
Registered Charity Number (RCN): 20030117.
©Design by LetterEleven